Luxembourg, 29/10/2004 (Agence Europe) - The refusal by a dominant pharmaceutical undertaking to meet all the orders of its customers in order to restrict parallel trade does not automatically constitute an abuse of a dominant position, states the Court of Justice in a press release, presenting the conclusions of Advocate General Jacobs in the "Syfait versus Glaxosmithkline" case.
This refusal cannot be considered abusive, given the specific nature of the European pharmaceuticals market and...